Cargando…

Serious safety events in rituximab‐treated multiple sclerosis and related disorders

INTRODUCTION: Studies investigating rates and risk factors for serious safety events (SSEs) during rituximab treatment of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and related disorders are limited. METHODS: Rituximab‐treated patients with MS, NMOSD, or related disord...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vollmer, Brandi L., Wallach, Asya I., Corboy, John R., Dubovskaya, Karolina, Alvarez, Enrique, Kister, Ilya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480911/ https://www.ncbi.nlm.nih.gov/pubmed/32767531 http://dx.doi.org/10.1002/acn3.51136

Ejemplares similares

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis
por: Vollmer, Brandi L., et al.
Publicado: (2022)

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions
por: Alvarez, Enrique, et al.
Publicado: (2022)

Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Piquet, Amanda L., et al.
Publicado: (2021)

Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab
por: Perriguey, Marine, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies
por: Wallach, Asya I., et al.
Publicado: (2022)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Disease exacerbation after rituximab induction in neuromyelitis optica
por: Perumal, Jai S., et al.
Publicado: (2015)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

COVID-19 outcomes in persons with multiple sclerosis treated with rituximab
por: Iyer, Rajesh B, et al.
Publicado: (2022)

Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies
por: Smith, Tyler Ellis, et al.
Publicado: (2021)

How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity
por: Kister, Ilya, et al.
Publicado: (2021)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study
por: Yamout, Bassem I., et al.
Publicado: (2018)

Evaluation of safety of rituximab in patients with multiple sclerosis: A retrograde study
por: Majdinasab, Nastaran, et al.
Publicado: (2020)

Emerging therapies for treatment of multiple sclerosis
por: Corboy, John R, et al.
Publicado: (2010)

Which symptoms contribute the most to patients’ perception of health in multiple sclerosis?
por: Green, Rivka, et al.
Publicado: (2017)

Prolonged COVID-19 in a Multiple Sclerosis Patient Treated With Rituximab
por: Kintrilis, Nikos, et al.
Publicado: (2022)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era
por: Kister, Ilya, et al.
Publicado: (2018)

Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland
por: Scotti, Barbara, et al.
Publicado: (2018)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Item response theory-based measure of global disability in multiple sclerosis derived from the Performance Scales and related items
por: Chamot, Eric, et al.
Publicado: (2014)

Rituximab for the treatment of multiple sclerosis: a review
por: Chisari, Clara Grazia, et al.
Publicado: (2021)

Corrigendum to “Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis”
Publicado: (2021)

Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective
por: Kasi, Pashtoon M, et al.
Publicado: (2012)

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
por: Gascón-Giménez, Francisco, et al.
Publicado: (2023)

Track density imaging of hypertrophic olivary degeneration from multiple sclerosis plaque
por: Hoch, Michael J, et al.
Publicado: (2016)

Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
por: Torgauten, Hilde Marie, et al.
Publicado: (2021)

Rituximab as Rescue Therapy for Aggressive Pediatric Multiple Sclerosis
por: Vartzelis, George, et al.
Publicado: (2019)

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
por: Brancati, Serena, et al.
Publicado: (2021)

Multiple Sclerosis Phenotypes as a Continuum: The Role of Neurologic Reserve
por: Vollmer, Timothy L., et al.
Publicado: (2021)

Periventricular Lesions Help Differentiate Neuromyelitis Optica Spectrum Disorders from Multiple Sclerosis
por: Raz, Eytan, et al.
Publicado: (2014)

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
por: Komori, Mika, et al.
Publicado: (2016)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging
por: Chawla, Sanjeev, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1i6d8msbsdae4c7k06sgaaspq7